JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Pharmacophore Based Screening and Molecular Docking Study of PI3K Inhibitors
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of the Chosun Natural Science
  • Volume 9, Issue 1,  2016, pp.41-61
  • Publisher : The Research Institute of Chosun Natural Science
  • DOI : 10.13160/ricns.2016.9.1.41
 Title & Authors
Pharmacophore Based Screening and Molecular Docking Study of PI3K Inhibitors
Rupa, Mottadi; Madhavan, Thirumurthy;
  PDF(new window)
 Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Phosphoinositide 3-kinases (PI3Ks) play important role in Non-Small Cell Lung Cancer. PI3Ks constitute a lipid kinase family which modulates the function of numerous substrates involved in the regulation of cell survival, cell cycle progression and cellular growth. Herein, we describe the ligand based pharmacophore combined with molecular docking studies methods to identify new potent PI3K inhibitors. Several pharmacophore models were generated and validated by Guner-Henry scoring Method. The best models were utilized as 3D pharmacophore query to screen against ZINC database (Chemical and Natural) and the retrieved hits were further validated by fitness score, Lipinski`s rule of five. Finally four compounds were found to have good potential and they may act as novel lead compounds for PI3K inhibitor designing.
 Keywords
PI3K;Non-small Cell Lung Cancer;3D Pharmacophore;
 Language
English
 Cited by
 References
1.
D. A. Fruman, R. E. Meyers, and L. C. Cantley, "Phosphoinositide kinases", Annu. Rev. Biochem., Vol. 67, pp. 481-507, 1998. crossref(new window)

2.
R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M. D. Waterfield, "Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer", Annu. Rev. Cell Dev. Biol., Vol. 17, pp. 615-675, 2001. crossref(new window)

3.
M. Graupera, J. Guillermet-Guibert, L. C. Foukas, L. K. Phng, R. J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P. R. Cutillas, A. J. H. Smith, A. J. Ridley, C. Ruhrberg, H. Gerhardt, and B. Vanhaesebroeck, "Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature", Nature, Vol. 453, pp. 662-666, 2008. crossref(new window)

4.
H. Z. Xie, L. L. Li, J. X. Ren, J. Zou, L. Yang, Y. Q. Wei, and S. Y. Yang, "Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors", Bioorg. Med. Chem. Lett., Vol. 19, pp. 1944-1949, 2009. crossref(new window)

5.
M. O. Taha, N. Atallah, A. G. Al-Bakri, C. Paradis-Bleau, H. Zalloum, K. S. Younis, and R. C. Levesque, "Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening", Bioorg. Med. Chem. Lett., Vol. 16, pp. 1218-1235, 2008. crossref(new window)

6.
H. Y. Wang, Z. X. Cao, L. L. Li, P. D. Jiang, Y. L. Zhao, S. D. Luo, L. Yang, Y. Q. Wei, and S. Y. Yang, "Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors", Bioorg. Med. Chem. Lett., Vol. 18, pp. 4972-4977, 2008. crossref(new window)

7.
J. Pothier, M. A. Riederer, O. Peter, X. Leroy, A. Valdenaire, C. Gnerre, and H. Fretz, "Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype", Bioorg. Med. Chem. Lett.., Vol. 22, pp. 4660-4667, 2012. crossref(new window)

8.
S. Y. Yang, "Pharmacophore modeling and applications in drug discovery: challenges and recent advances", Drug Discov. Today, Vol. 15, pp. 444-450, 2010. crossref(new window)

9.
S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw, and R. A. Friesner, "PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening", J. Comput. Aid. Mol. Des., Vol. 20, pp. 647-671, 2006. crossref(new window)

10.
M. M. Mysinger, M. Carchia, J. J. Irwin, and B. K. Shoichet, "Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking", J. Med. Chem., Vol. 55, pp. 6582-6594, 2012. crossref(new window)

11.
J. M. Yang and T. W. Shen, "A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators", Proteins, Vol. 59, pp. 205-220, 2005. crossref(new window)

12.
QikProp, Version 3.2, Schrodinger LLC, New York, USA, 2009.

13.
SYBYL Software, Version 7.3, Tripos Associates Inc, St. Louis, USA, 2006.